Study Shows Promise of Cyclophosphamide and Rituximab for Lupus Flares

The combination of intravenous cyclophosphamide and rituximab shows promise for the reduction of lupus flares, both renal and nonrenal, in patients with severe systemic lupus erythematosus, reported Dr. Ali Shahzad at the annual meeting of the ACR.

This benefit did not come at the cost of a significant increase in infections, as compared with intravenous cyclophosphamide monotherapy. The study was sponsored by the National Institutes of Health.